Based: New York
Stock symbol: OPHT
Range: $14 to $16
IPO price: $22.00
Close Oct. 17: $28.75
Change: Up 30%
Raised: $167 million

The scoop: Ophthotech's story played well with investors. It's run by an experienced crew that worked together at Eyetech. They have an intriguing late-stage program for Fovista, a drug for wet age-related macular degeneration. The treatment centers on platelet derived growth factor instead of VEGF. And it helped that the company has been hanging on to the worldwide rights to a drug that could be injected alongside the VEGF standard. In the end, they raised about twice what they had initially projected, and the stock has had a big spike since the recent debut. Ophthotech currently has a market cap of $1 billion, making it one of the biggest benefactors of the IPO boom.

For more:
Ophthotech, Foundation Medicine loot booming biotech IPO market for $273M
Ophthotech eyes $85M IPO to fund PhIII for drug to prevent blindness
Ophthotech nabs $30M round to fund AMD trial


Suggested Articles

Oncology is clearly a major medical and societal issue, but one that sees too much focus from biopharmas at the expense of other killers.

Durect’s share price fell 12% after half of the panel of painkiller experts recommended against approving Posimir.

China-based cancer and autoimmune disease biotech I-Mab Biopharma has raised $104 million on the U.S. Nasdaq composite.